AAPL277.62-15.55 (-5.30%) ▼|ABBV242.60+7.71 (+3.28%) ▲|ABT93.43+2.94 (+3.24%) ▲|ACN126.82-2.34 (-1.81%) ▼|ADBE195.34-1.21 (-0.62%) ▼|AMAT655.64+66.68 (+11.32%) ▲|AMD527.44+8.39 (+1.62%) ▲|AMGN355.90+4.51 (+1.28%) ▲|AMT170.24-4.22 (-2.42%) ▼|AMZN228.27-6.11 (-2.60%) ▼|AVGO381.34-0.75 (-0.20%) ▼|AXP344.12+1.56 (+0.46%) ▲|BA219.40-0.86 (-0.39%) ▼|BAC58.05+0.32 (+0.55%) ▲|BKNG178.94-2.34 (-1.29%) ▼|BLK971.24-11.36 (-1.16%) ▼|BMY55.78+0.78 (+1.41%) ▲|BNY144.95+1.39 (+0.97%) ▲|BRK-B488.50-6.32 (-1.28%) ▼|C145.22+1.63 (+1.13%) ▲|CAT1,050.59+56.14 (+5.64%) ▲|CL91.29-0.59 (-0.64%) ▼|CMCSA22.90+0.26 (+1.15%) ▲|COF204.53+4.05 (+2.02%) ▲|COP105.97-0.95 (-0.89%) ▼|COST940.60-20.37 (-2.12%) ▼|CRM150.25-2.51 (-1.64%) ▼|CSCO118.66-1.08 (-0.90%) ▼|CVS103.99+2.12 (+2.08%) ▲|CVX170.99-0.46 (-0.27%) ▼|DE621.35+20.60 (+3.43%) ▲|DHR194.83+5.96 (+3.15%) ▲|DIS99.09-2.04 (-2.01%) ▼|DUK126.65+0.12 (+0.09%) ▲|EMR145.24+3.80 (+2.69%) ▲|FDX326.72+9.89 (+3.12%) ▲|GD344.67+0.35 (+0.10%) ▲|GE373.06+7.18 (+1.96%) ▲|GEV1,092.51+34.86 (+3.30%) ▲|GILD124.62-0.53 (-0.42%) ▼|GM79.50+0.55 (+0.69%) ▲|GOOG340.03-5.00 (-1.45%) ▼|GOOGL340.93-4.35 (-1.26%) ▼|GS1,080.30+3.39 (+0.31%) ▲|HD344.04+1.18 (+0.34%) ▲|HON231.77+4.35 (+1.91%) ▲|IBM258.56-4.40 (-1.67%) ▼|INTC132.29+0.38 (+0.29%) ▲|INTU255.28-7.05 (-2.69%) ▼|ISRG400.33-1.50 (-0.37%) ▼|JNJ244.44+3.44 (+1.43%) ▲|JPM336.61+3.16 (+0.95%) ▲|KO80.19-0.41 (-0.51%) ▼|LIN525.13+9.40 (+1.82%) ▲|LLY1,126.44+9.18 (+0.82%) ▲|LMT505.55+13.91 (+2.83%) ▲|LOW222.11+0.66 (+0.30%) ▲|LRCX394.35+19.53 (+5.21%) ▲|MA493.92-0.50 (-0.10%) ▼|MCD266.45-7.43 (-2.71%) ▼|MDLZ62.05+0.31 (+0.50%) ▲|MDT81.37+1.24 (+1.54%) ▲|META545.53-12.28 (-2.20%) ▼|MMM168.34+2.43 (+1.46%) ▲|MO72.90+0.83 (+1.15%) ▲|MRK123.82+3.22 (+2.67%) ▲|MS222.01+2.15 (+0.98%) ▲|MSFT352.00-13.45 (-3.68%) ▼|MU1,220.22+172.30 (+16.44%) ▲|NEE87.36-0.26 (-0.29%) ▼|NFLX71.80-0.05 (-0.06%) ▼|NKE41.11-0.72 (-1.71%) ▼|NOW90.37-3.43 (-3.66%) ▼|NVDA195.49-3.42 (-1.72%) ▼|ORCL152.35-5.18 (-3.29%) ▼|PEP139.95-2.32 (-1.63%) ▼|PFE24.00-0.05 (-0.19%) ▼|PG149.24-2.81 (-1.84%) ▼|PLTR107.26-6.25 (-5.51%) ▼|PM178.24+0.93 (+0.52%) ▲|QCOM214.68+17.36 (+8.80%) ▲|RTX186.10+1.04 (+0.56%) ▲|SBUX103.26-0.27 (-0.26%) ▼|SCHW89.83-1.56 (-1.71%) ▼|SO95.48-0.30 (-0.31%) ▼|SPG224.96+2.81 (+1.26%) ▲|T22.46+0.09 (+0.38%) ▲|TMO510.45+18.25 (+3.71%) ▲|TMUS182.27+1.48 (+0.82%) ▲|TSLA374.76-0.71 (-0.19%) ▼|TXN313.48+10.37 (+3.42%) ▲|UBER72.92-0.93 (-1.26%) ▼|UNH414.76+8.96 (+2.21%) ▲|UNP265.58+5.62 (+2.16%) ▲|UPS108.78+2.64 (+2.48%) ▲|USB60.95+0.84 (+1.39%) ▲|V334.32+2.09 (+0.63%) ▲|VZ45.99+0.31 (+0.68%) ▲|WFC84.45+0.15 (+0.18%) ▲|WMT115.60-3.41 (-2.87%) ▼|XOM136.56-0.34 (-0.25%) ▼|AAPL277.62-15.55 (-5.30%) ▼|ABBV242.60+7.71 (+3.28%) ▲|ABT93.43+2.94 (+3.24%) ▲|ACN126.82-2.34 (-1.81%) ▼|ADBE195.34-1.21 (-0.62%) ▼|AMAT655.64+66.68 (+11.32%) ▲|AMD527.44+8.39 (+1.62%) ▲|AMGN355.90+4.51 (+1.28%) ▲|AMT170.24-4.22 (-2.42%) ▼|AMZN228.27-6.11 (-2.60%) ▼|AVGO381.34-0.75 (-0.20%) ▼|AXP344.12+1.56 (+0.46%) ▲|BA219.40-0.86 (-0.39%) ▼|BAC58.05+0.32 (+0.55%) ▲|BKNG178.94-2.34 (-1.29%) ▼|BLK971.24-11.36 (-1.16%) ▼|BMY55.78+0.78 (+1.41%) ▲|BNY144.95+1.39 (+0.97%) ▲|BRK-B488.50-6.32 (-1.28%) ▼|C145.22+1.63 (+1.13%) ▲|CAT1,050.59+56.14 (+5.64%) ▲|CL91.29-0.59 (-0.64%) ▼|CMCSA22.90+0.26 (+1.15%) ▲|COF204.53+4.05 (+2.02%) ▲|COP105.97-0.95 (-0.89%) ▼|COST940.60-20.37 (-2.12%) ▼|CRM150.25-2.51 (-1.64%) ▼|CSCO118.66-1.08 (-0.90%) ▼|CVS103.99+2.12 (+2.08%) ▲|CVX170.99-0.46 (-0.27%) ▼|DE621.35+20.60 (+3.43%) ▲|DHR194.83+5.96 (+3.15%) ▲|DIS99.09-2.04 (-2.01%) ▼|DUK126.65+0.12 (+0.09%) ▲|EMR145.24+3.80 (+2.69%) ▲|FDX326.72+9.89 (+3.12%) ▲|GD344.67+0.35 (+0.10%) ▲|GE373.06+7.18 (+1.96%) ▲|GEV1,092.51+34.86 (+3.30%) ▲|GILD124.62-0.53 (-0.42%) ▼|GM79.50+0.55 (+0.69%) ▲|GOOG340.03-5.00 (-1.45%) ▼|GOOGL340.93-4.35 (-1.26%) ▼|GS1,080.30+3.39 (+0.31%) ▲|HD344.04+1.18 (+0.34%) ▲|HON231.77+4.35 (+1.91%) ▲|IBM258.56-4.40 (-1.67%) ▼|INTC132.29+0.38 (+0.29%) ▲|INTU255.28-7.05 (-2.69%) ▼|ISRG400.33-1.50 (-0.37%) ▼|JNJ244.44+3.44 (+1.43%) ▲|JPM336.61+3.16 (+0.95%) ▲|KO80.19-0.41 (-0.51%) ▼|LIN525.13+9.40 (+1.82%) ▲|LLY1,126.44+9.18 (+0.82%) ▲|LMT505.55+13.91 (+2.83%) ▲|LOW222.11+0.66 (+0.30%) ▲|LRCX394.35+19.53 (+5.21%) ▲|MA493.92-0.50 (-0.10%) ▼|MCD266.45-7.43 (-2.71%) ▼|MDLZ62.05+0.31 (+0.50%) ▲|MDT81.37+1.24 (+1.54%) ▲|META545.53-12.28 (-2.20%) ▼|MMM168.34+2.43 (+1.46%) ▲|MO72.90+0.83 (+1.15%) ▲|MRK123.82+3.22 (+2.67%) ▲|MS222.01+2.15 (+0.98%) ▲|MSFT352.00-13.45 (-3.68%) ▼|MU1,220.22+172.30 (+16.44%) ▲|NEE87.36-0.26 (-0.29%) ▼|NFLX71.80-0.05 (-0.06%) ▼|NKE41.11-0.72 (-1.71%) ▼|NOW90.37-3.43 (-3.66%) ▼|NVDA195.49-3.42 (-1.72%) ▼|ORCL152.35-5.18 (-3.29%) ▼|PEP139.95-2.32 (-1.63%) ▼|PFE24.00-0.05 (-0.19%) ▼|PG149.24-2.81 (-1.84%) ▼|PLTR107.26-6.25 (-5.51%) ▼|PM178.24+0.93 (+0.52%) ▲|QCOM214.68+17.36 (+8.80%) ▲|RTX186.10+1.04 (+0.56%) ▲|SBUX103.26-0.27 (-0.26%) ▼|SCHW89.83-1.56 (-1.71%) ▼|SO95.48-0.30 (-0.31%) ▼|SPG224.96+2.81 (+1.26%) ▲|T22.46+0.09 (+0.38%) ▲|TMO510.45+18.25 (+3.71%) ▲|TMUS182.27+1.48 (+0.82%) ▲|TSLA374.76-0.71 (-0.19%) ▼|TXN313.48+10.37 (+3.42%) ▲|UBER72.92-0.93 (-1.26%) ▼|UNH414.76+8.96 (+2.21%) ▲|UNP265.58+5.62 (+2.16%) ▲|UPS108.78+2.64 (+2.48%) ▲|USB60.95+0.84 (+1.39%) ▲|V334.32+2.09 (+0.63%) ▲|VZ45.99+0.31 (+0.68%) ▲|WFC84.45+0.15 (+0.18%) ▲|WMT115.60-3.41 (-2.87%) ▼|XOM136.56-0.34 (-0.25%) ▼|
28.3 C
New York
Thursday, June 25, 2026

Tag: Corporate

newssourceFORcompanyinformationcontent1marketreleases

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Immutep (IMMP) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/6/2026

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...

Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...

Bronstein, Gewirtz & Grossman LLC Urges CommVault Systems, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for CommVault (CVLT) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 7/17/2026

Bronstein, Gewirtz & Grossman LLC Urges POET Technologies Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for POET Technologies Inc. urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 6/29/2026

Bitty & Beau’s Coffee Launches New Mini Cruiser Franchise Model

Nationally recognized coffee brand introduces a lower-cost mobile franchise designed to expand inclusion, opportunity, and entrepreneurship nationwide. ...

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

Dongfeng Liuzhou Motor’s 10th “67 Brand Customer Day” Advancing New Pathways for Global Growth

LIUZHOU, China, June 7, 2026 /PRNewswire/ -- On June 7, Dongfeng Liuzhou Motor (DFLZM) hosted its 10th "67 Brand Customer Day" in Liuzhou. More than...

Dongfeng Liuzhou Motor’s 10th “67 Brand Customer Day” Advancing New Pathways for Global Growth

LIUZHOU, China, June 7, 2026 /PRNewswire/ -- On June 7, Dongfeng Liuzhou Motor (DFLZM) hosted its 10th "67 Brand Customer Day" in Liuzhou. More than...

Communiqué Orange : Signing of a Memorandum of Understanding for the acquisition of SFR

Press release
Paris, 6 June 2026

Communiqué Orange : Signature d’un protocole d’accord en vue de l’acquisition de SFR

Communiqué de presse
Paris, le 6 juin 2026

Faguy & Co. Investigates TerraVest Industries Inc. (TSX:TVK)

MONTREAL, June 6, 2026 /CNW/ - Faguy & Co., a leading Canadian plaintiff-side litigation law firm, is investigating a possible securities class action on...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCorporate

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers